24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of September and added some color.
Ellen H Ullman, MSW's insight:
Zosano Pharma Corp. (NASDAQ: ZSAN) recently completed its enrollment for the Phase 2 trial for ZP-Glucagon. If it is approved by the FDA, it has the potential to be a significant improvement over the currently marketed products for treatment of severe hypoglycemia, which often require a lay person to deliver an injection after a cumbersome preparation process. The company anticipates announcing top-line data from the trial around September. Shares of Zosano ended the week at $8.10, in its 52-week range of $7.01 to $12.40. The consensus analyst price target is $21.00.
This is a rant. An emotionally charged rant that comes from a variety of thoughts and emotions in my head about a variety of experiences...but I know it's one you'll probably understand.Part of what initially sparked these emotions was this post from mom-blogger at TheMighty.com af
Insulet said its long-troubled Billerica, MA manufacturing plant is back on track on an earnings call earlier this month--just before the FDA offered details on the OmniPod recalls that were caused by inadequate standards compliance.
In 1967, my parents decided to send me to private school and in September I had the required physical exam. Just after the exam, my mom took me down to a lab, and I had my blood taken. When I asked her why, she said something about diabetes, but added, “don’t worry, you don’t have diabetes”. A few days later she said I had to go to Children’s Hospital in Washington DC, and did not tell me why. When I got there, the receptionist looked at me and said, “oh this is the little girl with diabetes...
This week Corinna and Mike talk about diabetes technology. They also play the interview we did with Scott Scolnick from the Bionic Pancreas Team which is a collaborative group from Boston University and Massachusetts General Hospital working together to make automated blood glucose control a reality. Mike asks the question, “Would fully automated diabetes management be …
Diabetes devices are life-enhancing. For the most part they give us remarkable capacity to better manage our health. But we must recognize that new technology also adds effort, frustration, discomfort, confusion and expense to patients' lives.
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.